Highlight
– Sequential administration of parecoxib followed by imrecoxib significantly reduced the occurrence of severe acute pancreatitis (SAP) by 20.7% compared to placebo.
– The duration of persistent organ failure (OF) was shortened by two days in patients treated with COX-2 inhibitors.
– Local complications and systemic inflammatory mediators were notably less frequent and reduced, respectively, after COX-2-Is treatment.
– The 30-day mortality rate dropped from 8.6% in the placebo group to 3.4% with sequential COX-2 inhibitor therapy, with a similar adverse event profile between treatment groups.